|Videos|June 24, 2020

Applying Cancer Knowledge to COVID Vaccine Research

Author(s)Contagion&reg Editorial Staff

Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio, explains why the firm's COVID-19 research benefits from drawing on a background in cancer.

Segment Description: Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio, explains why the firm's COVID-19 research benefits from drawing on a background in cancer.

Part 1: SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?

Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Part 2: Goals of Operation Warp Speed

Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, describes goals and expectations for the accelerated coronavirus vaccine program Operation Warp Speed.

Part 3: Justice & American Values During the Coronavirus Pandemic

Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, discusses the pandemic as a unique moment in world & American history.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Related to this article

October 25th, 2026

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants

Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.

October 22nd, 2026

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE

In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.

November 2nd, 2026

Washington State Reports First US Avian Influenza Death of 2026

A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.

November 2nd, 2026

FDA Approves Voceryq, First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis

Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.

November 2nd, 2026

Cefiderocol Activity Improves in Physiologic Media, Synergizes With LL-37

Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.

October 30th, 2026

Measles Update: October 30, 2026

The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.

October 29th, 2026

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections

Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.